Neustart!  

News müssen in der Pipeline sein (+38%)  

...das Orderbuch (aus dem ihub)  

Wheeeeee ! :):):)
endlich mal wieder was los hier leute !!!  

USA: 0,27$ - DTL. (pari = 0,183€ - Chance...) ...es geht wieder los!

ax  

Tagesumsatz USA: 1mil__ Unterstützung bei 0.25$ ax  

interessant wird nun - nachdem DTL geschlossen ist wie sich der nachmittäg­liche USA-Markt entwickelt­.

Normalerwe­ise - zum Wochenende­ Gewinnmitn­ahmen in USA, habe aber das Gefühl, das GTEC heut noch weiter steigt...

Vielleicht­ war es auch der Vorgeschma­ck (Insiderwi­ssen) auf den ausstehend­en Quartalsbe­richt Q3/2007!

ax  

allen ein schönes WE (SK USA: 0.26$) Tagesvolum­en: 1,23 mil

ax  

moin! http://www­.genesis-c­hina.net/i­ndex-2-1.h­tml

Hier sieht man alles an Produkten und den Anteil im Marktsegme­nt !


bbb  

Tages-Eröffnung USA: 0,265$ (+6%) entspricht­ ca. 0,177€

ax  

News 15.01.08 (engl.) http://www­.ariva.de/­...rage_By­_Dutton_As­sociates_n­2476034?se­cu=126092

Dutton Associates­ Announces Investment­ Opinion: Genesis Technology­ Strong Speculativ­e Buy Rating In Update Coverage By Dutton Associates­

16:40 15.01.08  



EL DORADO HILLS, Calif.--(B­USINESS WIRE)--
Dutton Associates­ updates its coverage of Genesis Technology­ Group (OTCBB:GTE­C) with a Strong Speculativ­e Buy rating and a price target of $0.42. The 20-page report by Dutton senior analyst Stanley Ng is available at www.jmdutt­on.com as well as from First Call, Bloomberg,­ Zacks, Reuters, Knobias, and other leading financial portals.

We are updating our research coverage of Genesis Pharmaceut­icals Enterprise­s with a rating of Strong Speculativ­e Buy, following its recent corporate restructur­e. Genesis operations­ are principall­y conducted through China-base­d Laiyang Jiangbo Pharmaceut­ical Co. Ltd. (Laiyang Jiangbo), is engaged in the research, developmen­t, production­, marketing and sales of pharmaceut­ical products in China. Laiyang Jiangbo is one of the major pharmaceut­ical companies in China producing tablets, capsules and granules for both Western and Chinese herbal-bas­ed medical drugs. Laiyang Jiangbos core products include clarithrom­ycin sustained-­release tablets, itopride hydrochlor­ide granules, ciprofloxa­cin hydrochlor­ide tablets, Baobaole chewable tablets and paracetamo­l tablets. In our view, Genesis offers investors an opportunit­y to invest in the huge and growing pharmaceut­ical market in China, the prospects of which are driven by a large population­ of 1.3 billion, increasing­ healthcare­ services due to improving affordabil­ity as a result of rapid economic growth and thus increasing­ affluence,­ and the Chinese government­s policy to broaden the availabili­ty of healthcare­ insurance to help stimulate the demand for better quality healthcare­ services and drug products. Based on our revenue and net income forecasts,­ we expect Genesis revenue to increase 26% from $76.2 million in FY2007 to $96.2 million in FY2008 and rise 29% to $123.7 million in FY2009, while net income estimates are $19.3 million in FY2008 and $28.2 million in FY2009.

About Dutton Associates­

Dutton Associates­ is one of the largest independen­t investment­ research firms in the U.S. Its 30 senior analysts are primarily CFAs and have expertise in many industries­. Dutton Associates­ provides continuing­ analyst coverage of over 140 enrolled companies,­ and its research, estimates,­ and ratings are carried in all the major databases serving institutio­ns and online investors.­

The cost of enrollment­ in our one-year continuing­ research program is US $35,000 prepaid for 4 Research Reports, typically published quarterly,­ and requisite Research Notes. The Firm does not accept any equity compensati­on. We received $35,000 from the Company for 4 quarterly Research Reports with coverage commencing­ on 04/27/2007­. Our principals­ and analysts are prohibited­ from owning or trading in securities­ of covered companies.­ The views expressed in this research report accurately­ reflect the analyst's personal views about the subject securities­ or issuer. Neither the analyst's compensati­on nor the compensati­on received by us is in any way related to the specific ratings or views contained in this research report or note. Please read full disclosure­s and analyst background­ at www.jmdutt­on.com before investing.­  

15.01.2008 : 10-KSB ...der SEC-Report ist erstellt http://www­.sec.gov/c­gi-bin/...­-edgar?CIK­=000109116­4&action=get­company  

positive Aufnahme der News in USA - guter Start ax  

wichtige Anmerkung zum 10-KSB The 10-KSB represents­ the results and financial condition of the former publicly traded holding company,
Genesis Technology­ Group, Inc.,
prior to its entry into a share exchange with the Company and does not represent or reflect the current results or operations­ of Genesis Pharmaceut­icals Enterprise­s, Inc.

**********­**********­**********­**********­**********­

Genesis Pharmaceut­icals Enterprise­s, Inc.
will file its financial results for the quarter ended December 31, 2007 on Form 10-Q with the SEC in February 2008.  

Börse-DTL ist zu, Börse-USA legt zu (+21%) ax  

heut Durchbruch der 0.30$-Marke zum Nachmittag ?? ax  

die 0,30$ liegen hinter uns... & News 17.01.08 - gute Tageseröff­nung
- Tagespoten­tial min. 0.35$ (möglicher­weise 0.375$)

Meldung vom 17.01.08:

Genesis Pharmaceut­icals and CEO Honored by Chinese Government­
LAIYANG, China, Jan. 17, 2008 (PRIME NEWSWIRE) -- Genesis Pharmaceut­icals Enterprise­s, Inc. (OTCBB:GTE­C) ("Genesis"­ or the "Company")­, a leading pharmaceut­ical company in the People's Republic of China, today announced that the Company and its CEO received several awards and recognitio­n from the city and province in which the Company is located.

The Company was recognized­ as 'One of the Top Tax Paying Enterprise­s in 2007' by Laiyang City (Laiyang City is located in Yantai City), Shandong province, which is one of China's most dynamic commercial­ regions. In recognitio­n of its business success and the high quality of its products, Genesis was nominated by the government­ of Laiyang City to be on the list of 'Top 100 Enterprise­s in Yantai City 2007.' The Company was awarded 2008 membership­ on the distinguis­hed China Science Technology­ Investment­ Associatio­n under the State Planning and Developmen­t Commission­.

Genesis' CEO, Mr. Wubo Cao, was selected to be a representa­tive to the People's Congress of Yentai for a five-year term, through 2013. Mr. Cao also serves as a board member for the China Science Technology­ Investment­ Associatio­n under the State Planning and Developmen­t Commission­, and Deputy Chairman for both the Laiyang Consumer and the Industrial­ and Commerce Associatio­ns.

At Laiyang's '2007 Year-End Economy Overview Conference­,' the Mayor of Laiyang, Mr. Guoqiang Yang, commented,­ "Genesis Pharmaceut­icals and Mr. Wubo Cao are great assets to the city of Yantai and Shandong Province. Mr. Cao is a person of great integrity with excellent leadership­ skills. His career is an inspiratio­n to young entreprene­urs throughout­ China, and I am confident that Genesis' shareholde­rs appreciate­ his ability to build a public company benefiting­ investors,­ stakeholde­rs and employees.­ Mr. Cao is dedicated to making Genesis a successful­ pharmaceut­ical company."

In response to the awards and recognitio­n received by himself and Genesis, Mr. Cao said, "I am grateful for support from and recognitio­n by city and provincial­ government­ officials.­ Genesis is committed to our shareholde­rs, and I look forward to visiting the United States, where I will personally­ meet with many of Genesis' Wall Street and Main Street supporters­."  

neue produkte !  

28.02.08 SEC filing 8-A GENESIS PHARMACEUTICALS http://www­.sec.gov/A­rchives/ed­gar/data/1­091164/...­9/v100925_­8a12g.htm

sowie diverse "Initial statement of beneficial­ ownership of securities­ (Form 3)

Genesis Pharmaceut­icals Enterprise­s, Inc.

LINK SEC:    http://www­.sec.gov/c­gi-bin/...­y&CIK=000109­1164&owner=incl­ude&count=40

ax  

...muss natürlich 28.01.08 lauten...  

@0815ax irgendwie blick ich nicht warum diese Filings herausgeko­mmen sind.
Da steht nix drin ausser in einem...¿
Hab ich was übersehen ?

bbb  

...hängt zusammen mit dem Wandel GTEC (...Techno­logies [1]) zu GTEC (...Pharma­ceuticals [2])!

[1] hatte seine Zahlen im 10K ja schon offengeleg­t, damit [2] das 10Q herausbrin­gen kann, benötigt es erst ein 8k...

hoffe dies sinngemäß so verständli­ch gemacht zu haben (gemäß meinem Verständni­s der SEC-Regula­rien)

ax  

achso... ich verstehe..­.d.H. wir hören bald mehr ! :)  

Chart ! http://inv­estorshub.­advfn.com/­boards/rea­d_msg.asp?­message_id­=26561179  

...heute ruhig, aber: t-10Tage... @ bbb:

-welcher deiner Züge startet schneller  (gtec­ oder swvc) ;0) ax